Abstract
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic. Recent advances in our understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors. © 2006 American Association for Cancer Research.
Original language | English |
---|---|
Pages (from-to) | 5268-5272 |
Journal | Clinical Cancer Research |
Volume | 12 |
Issue number | 18 |
DOIs | |
Publication status | Published - 15 Sep 2006 |